Moleculin Biotech Inc. (MBRX) |
|
0.8557 -0.024 (-2.76%)
|
07-10 16:00 |
|
Open: |
0.86 |
Pre. Close: |
0.88 |
|
High:
|
0.88 |
Low:
|
0.84 |
|
Volume:
|
713,736 |
Market Cap:
|
52M |
|
|
|
|
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and lung-localized tumors. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.882 - 0.887 |
0.887 - 0.892 |
|
Low:
|
0.826 - 0.832 |
0.832 - 0.838 |
|
Close:
|
0.85 - 0.859 |
0.859 - 0.87 |
|
Technical analysis |
as of: 2020-07-10 4:30:02 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.24 One year: 1.42 |
| Support: |
Support1: 0.81 Support2: 0.68 |
| Resistance: |
Resistance1: 1.06 Resistance2: 1.22 |
| Pivot: |
0.95  |
| Moving Average: |
MA(5): 0.88 MA(20): 0.98
MA(100): 0.92  MA(250): 0.99 |
| MACD: |
MACD(12,26): -0.05 Signal(9): -0.04 |
| Stochastic oscillator: |
%K(14,3): 22.75 %D(3): 21.43 |
| RSI: |
RSI(14): 27.65 |
| 52-week: |
High: 1.97 Low: 0.32 Change(%): -29.9 |
| Average Vol(K): |
3-Month: 202060 10-Days: 92695 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.MBRX has closed above bottom band by 5.4%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to MBRX's normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 07 Jul 2020
Is Moleculin Biotech, Inc. (MBRX) a Keeper? Bullish Price Target $5.00 - The News Heater
Tue, 07 Jul 2020
Moleculin Biotech Inc. (NASDAQ:MBRX) is Waving the Bear Flag - The Oracle Dispatch
Thu, 02 Jul 2020
Moleculin Biotech Inc. (MBRX) volume hits 1.06 million: A New Opening for Investors - News Daemon
Wed, 01 Jul 2020
Moleculin Biotech (MBRX) Announces New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model - StreetInsider.com
Wed, 01 Jul 2020
Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Fri, 26 Jun 2020
Moleculin Biotech, Inc. (MBRX): Skating on Thin Ice? Beta Stands at 2.40 - The News Heater
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Capital Market |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
60 |
| Shares Float (M) |
46 |
|
% Held by Insiders
|
11.45 |
|
% Held by Institutions
|
20.38 |
|
Shares Short (K)
|
4,250 |
|
Shares Short P. Month (K)
|
4,040 |
Stock Financials |
|
EPS
|
-0.226 |
|
EPS Est This Year
|
-0.340 |
|
EPS Est Next Year
|
-0.360 |
|
Book Value (p.s.)
|
0.290 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-48.2 |
|
Return on Equity (ttm)
|
-69.2 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.295 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-18 |
|
Levered Free Cash Flow (M)
|
-14 |
Stock Valuations |
|
PE Ratio
|
-3.79 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.95 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-2.92 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
